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A B S T R A C T 
Hypertension is a significant risk factor for cardiovascular diseases. It closely related to 
the inflammatory process and resulting in chronic inflammation, which had a critical role 
in the progression of atherosclerosis. Carotid Intima-Media Thickness (CIMT) was known 
as a surrogate marker of atherosclerosis. Anti-hypertensive drugs are expected to affect 
CIMT. Aim: to examine the difference CIMT between newly diagnosed hypertension and 
chronic hypertensive treated by ACE-I or CCB. Method: this cross-sectional study was 
conducted on 12 newly diagnosed hypertensive patients (control or group 1), 9 
hypertensive patients treated by CCB (group 2), and 9 hypertensive patients treated by 
ACE-I (group 3). Their hypertensive condition was controlled at least for 6 months. We 
compared CIMT of patients and Tumour Necrosis Factor Alfa (TNF-α) also Interleukin-6 
(IL-6) among the groups. Result: there was a significant difference in CIMT between the 
group 1 and 2 (0.86 vs 0.70; p = 0.027), group 1 and 3 (0.86 vs 0.69; p = 0.018). There was 
no significant difference between group 2 and 3 (0.70 vs 0.69; p = 0.88). There was no 
association between CIMT and TNF-α, IL-6, Low-Density Lipoprotein (LDL), triglycerides 
(TGs) levels, and body mass index (BMI), systolic blood pressure. Conclusion: we found that 
the CIMT of the control group was thicker than those of the treatment groups. Moreover, 
differences in the thickness of CIMT of the three groups were not associsted with level of 
TNF-α, IL-6, TG, and LDL, also BMI, and systolic blood pressure. 
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I N T R O D U C T I O N 
Hypertension is a condition that occurs due to 
interactions between genetic factors and 
environmental factors.[1,2] In its development, the 
vascular inflammation process is known to have a role 
in the pathophysiology of essential hypertension.[3] 
Inflammation has a chemokine receptor that plays a 
critical role in the process of adhesion and leukocyte 
recruitment in endothelial cells.[4,5] C - Reactive 
protein (CRP), Interleukin-6 (IL-6), and Tumour 
Necrosis Factor-alpha (TNF-α) are independent risk 
factors for the development of hypertension.[6] 
Hypertension also causes a chronic inflammation, 
which is suspected to be very closely related to 
vascular inflammation, which we recently knew to 
have an essential role in the process of 
atherosclerosis.[7,8,9] 
Carotid artery intima-media thickness (IMT) 
or carotid artery thickness and carotid artery media 
are markers of atherosclerosis[10] that are 
independently associated with cardiovascular 
events.[11,14] We obtained the pieces of evidence from 
various clinical studies that support a direct effect on 
the vascular of Angiotensin Converting Enzyme 
Inhibitors (ACE-I) Inhibition. The Trial on Reversing 
Endothelial Dysfunction (TREND) study showed that 
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after 6 months of therapy with ACE-I, Quinapril could 
repair endothelial dysfunction in patients given by 
acetylcholine to provoke vasoconstriction.[15]  
Referring to the background of this present 
study, we encountered various studies that have 
developed to look for Beyond Blood Pressure 
Lowering Effect of other anti-hypertensive drugs.[16] 
Some studies explained Calcium Channel Blocker 
(CCB) could inhibit the progression of atherosclerosis 
and reduce the risk of cardiovascular disease.[17] 
Considering the mechanism of action of CCB 
drugs serves intracellular calcium ions, where 
calcium ions are essential second messenger in the 
cell signaling process, we expected that CCB has a role 
that is more than anti-hypertension. Calcium ions can 
stimulate the production of endothelial nitric oxide 
(eNOS), prostaglandins, and Nitric Oxide (NO) 
through calcium-calmodulin complex bonds. It has a 
role not only as potent vasodilators but also have anti-
platelet aggregation effects. It also prevents the 
proliferation of smooth muscle cells (SMC) that play a 
crucial role as an atheroprotective factor.[18] 
We conducted this study to examine the thickness 
of carotid intima-media in hypertensive patients 
who had not received therapy, and hypertensive 
patients who had received ACE-I therapy or CCB 
therapy. We hypothesize that there is a difference in 
thickness of carotid intima-media between the 
control group and the two treatment groups.  
M E T H O D S 
Study Design  
We conducted this study with a cross-
sectional approach to compare CIMT, TNF-α, and IL-
6 between hypertensive patients with stage 1 and 2 
hypertension who had never received therapy and 
who had received ACE-I or CCB treatment at Saiful 
Anwar Hospital Malang, for at lest 6-months. The 
hypertensive patients were selected from those 
referred to the outpatient clinic in this hospital. We 
undertook patients using the following sampling 
method. The inclusion criteria were all patients 
with stage 1 and 2 hypertension who had never 
received therapy and who had received ACE-I or 
CCB treatment, at least, for 6 months. We called the 
first group as a control group (group 1). The second 
group with ACE-I therapy called as group 2. The last 
group with CCB treatment as group 3. All groups 
had an age between 40 to 60 years. Exclusion 
criteria of all groups were patients who suffered 
from active infections, glomerular filtration rate 
(GFR) < 60 ml/min, suffered from heart failure, 
Systemic Lupus Erythematosus (SLE), Rheumatoid 
Arthritis (RA), diabetes mellitus, and using drugs 
that have anti-inflammatory effects.  
The research protocol was approved by the 
local ethics committee. We had informed about the 
aim and the suspected benefit of the study before 
getting their agreements for participation. Then, 
participants completed and signed the written 
informed consent. There were no additional 
Interventions by us on the hypertensive patients of 
this study.  
Study Procedures  
This study collected the data from each 
patient with a diagnosis of hypertension based on the 
JNC 7 guidelines. All patients’ anamnesis, physical 
examination, several laboratory parameters at Saiful 
Anwar Hospital, Malang. The electrocardiography, 
chest X-ray, and B-mode ultrasonography were 
performed to determine the thickness of CIMT. The 
evaluation was carried out blindly by experienced 
radiologists and cardiologists. 
To find out factors related to differences in 
CIMT thickening, we noted the types of 
antihypertensive drugs, measured TNF-α, IL-6, 
changes in body mass index (BMI), systolic blood 
pressure, LDL and TG levels.  
Statistical analysis 
Quantitative variables are expressed as a 
mean and standard deviation, and compared using 
one-way ANOVA to compare the CIMT, TNF-α, and IL-
6 between the control group and two treatment 
groups followed by post-hoc test, LSD. Qualitative 
variables are expressed as percentage and compared 
using the Chi-square or Fisher exact test. All technical 
data processing results were analysed by 
computerization using Statistical Product and Service 
Solution software, IBM SPSS Statistics 20, with a 
significance level of 0.05 (α=0.05). 
R E S U L T S 
We included a total number of 30 
hypertensive patients in this study. The groups were 
divided into three. It consists of 12 hypertensive 
patients who had never received therapy, 9 
hypertensive patients who had received ACE-I 
therapy, and 9 hypertensive patients who had 
received CCB therapy. 
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Figure 1. Diagram of Data Collection  
We analyzed 30 hypertensive patients who 
had a complete database statistically, with the 
characteristics of the patients as described in figure 
1. The patients consisted of 7 men (23.3%) and 23 
women (76.7%) who attended the outpatient clinic 
of Saiful Anwar Hospital Malang. 
There are several factors that cause CIMT 
thickening in a number of research subjects which 
were BMI >25kg/m2 in 7 patients (23.3%), LDL 
>150mg/dl in 12 patients (40.0%) and TG 
>130mg/dl in 15 patients (50%), systolic blood 
pressure >160 mmHg (86.7%). 
The Difference of CIMT, IL-6, and TNF-α among the 
groups  
We subjected all patients who met the 
inclusion criteria to clinical tests, laboratory 
evaluations, and B-mode ultrasonography to assess 
the thickness of the CIMT.  
Table 1. Baseline Characteristics of Subjects 
 
Variables 









































































Data presented as mean ± SD, BMI: body mass index; SBP, systolic 
blood pressure; LDL: low-density lipoprotein; TG, triglyceride; TNFα: 
Tumour Necrosis Factor-α, IL-6: interleukin-6; CIMT: carotid intima-
media thickness. 
As described in the baseline characteristics 
of the subjects above, we obtained a different CIMT 
between each group. The CIMT values of patients in 
the three groups ranged from 0.60 to 1.30. The 
lowest (minimum) value of 0.50 was obtained in the 
group of patients on ACE-I therapy, while we 
received the highest value (maximum) of 1.30 in the 
control group. Here is Figure 2 presents the mean 
(blue bar graph) showing the measures of central 
tendency, as well as the standard deviation. 
 
 
Figure 2. Histogram difference in CIMT among Groups 
TNFα: Tumour Necrosis Factor-α, IL-6: interleukin-6; CIMT: 
carotid intima-media thickness. 
Table 2. Differences in CMIT, TNF-α, and IL-6 among groups 
Data presented as mean and SD, *one-way ANOVA. 
TNFα: Tumour Necrosis Factor-α, IL-6: interleukin-6; CIMT: carotid 
intima-media thickness. 
We concluded that there were significant 
differences in CIMT values among the three groups.  
The difference of mean measurement of CIMT 
between the groups was statistically significant 
(ANOVA, p= 0.027). Moreover, posthoc analysis 
tests results were statistically significant; we found 
that there was a significant difference between the 
CIMT control groups and the CIMT groups who had 
received ACE-I or CCB therapy (p= 0.027 and p= 
0.018). Still, there was no significant difference in 
the CIMT between the ACE-I and CCB therapy groups 
(p= 0.879). 
The results of the analysis of the TNF-α and 
IL-6 obtained p=0.270 and 0.052, respectively. We 
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concluded that there were no significant differences 
in the TNF-α and IL-6 between the three groups. 
Based on the assessment, there was a significant 
difference between the IL-6 in the control group and 
the ACE-I group (p= 0.017). 














































Post-hoc LSD; * indicated statistically significant; TNFα: Tumour 




Figure 2. Histogram differences in TNF-α levels with respect to 
CIMT.  
Data presented as mean and SD. TNFα: Tumour Necrosis Factor-α, 
CIMT: carotid intima-media thickness. 
 
Figure 3. Histogram differences in IL-6 levels with respect to 
CIMT. 
Data presented as mean and SD. IL-6: interleukin-6; CIMT: carotid 
intima-media thickness. 
As described in (Figure 2) and (Figure 3), we 
could see that the average level of TNF-α and IL6 on 
thickened CIMT is higher than non-thickened CIMT, 








Non-thickened CMIT P 
TNF-α 
(ng/ml) 
2.95 3.09 0,618 
IL-6 
(ng/ml) 
16.43 16.85 0,808 
*TNFα, Tumour Necrosis Factor-α; IL-6, interleukin-6; CIMT, carotid 
intima-media thickness. 
The Differences of BMI, LDL level, TG level, and 
Systolic blood pressure among groups. 
According to previous studies, several factors 
could influence the CIMT, including BMI, LDL levels, 
TG levels, and blood pressure. For this reason, we 
analyzed each variable among groups. There was no 
difference statistically in term of LDL level, TG level, 
and blood pressure among groups (Table 5). 
Table 5. Difference of BMI, LDL level, TG level, and Systolic 
blood pressure among groups 
BMI, body mass index; SBP, systolic blood pressure; LDL, low 
density lipoprotein; TG, triglyceride.  
On the other hand, there were significant 
differences in BMI between group 2 and control 
group (P= 0.046) and between group 2 and group 3 
(p= 0.028) (Table 6). 
Table 6. Difference of BMI among groups 






















Data presented as mean. BMI, body mass index.  
From the CIMT Analysis of the TNF-α, IL-6, 
BMI (> 25 kg/m2 and <25 kg/m2), TDS (> 160 and 
<160), LDL (> 130 and <130) and TG (> 150 and 
<150), we found that there was a significant 
difference in CIMT (Table 7). 
 
Table 7. The Comparison of mean CMIT Thickening based on 































































































*BMI, body mass index; LDL, low density lipoprotein; TG, triglyceride, 
SBP; systolic blood pressure.  
 
  
Figure 4. Histogram of CIMT based on BMI, LDL, TG and Systolic 
Blood Pressure. 
BMI, body mass index; LDL, low density lipoprotein; TG, 
triglyceride; SBP, systolic blood pressure.  
(Table 7) and (Figure 4) showed that the mean of 
CIMT was thicker on BMI > 25 kg/m2, as well as at 
SBP>160 mgHg, but in both of TG groups, the mean of 
CIMT was not different. Even in the LDL, the CIMT was 
thicker in LDL <130 mg/dl. From the test results 
showed that the p>0.05 on all variables, which means 
there was no significant difference from the CIMT on 
BMI group (normal and obese), LDL level (normal and 
above 150 mg/dl), TG level (below 130 mg/dl and 
above 130 mg/dl), and SBP (under 160 mmHg and 
above 160 mmHg). 
D I S C U S S I O N 
The Differences of CIMT in hypertensive patients 
Our study showed, that there was a significant 
difference between the CIMT of the control group and 
the hypertensive group who had received therapy 
(treated groups). We found the lowest CIMT in the 
group 3 (CIMT of control was 0.86 ± 0.06 (0, 60-1.0); 
ACE-I was 0.70 ± 0.04 (0.50-0.90); and CCB was 0.69 
± 0.02 (0.60-0.75); p= 0.027). 
Hypertension is an important risk factor for 
cardiovascular complications [19], especially stroke.[20] 
It also has an important complex role in the 
pathogenesis of atherosclerosis. A continual elevated 
in blood pressure caused changes in vascular 
endothelial function, such as increased vascular 
permeability, decreased endothelial vasodilators, and 
increased adherence of leukocytes on the surface of 
the endothelium to the accumulation of macrophages 
in the intima layer. [8, 9, 21] 
Hypertension also increases vascular smooth 
muscle cell (VSMC) proliferation. On the 
other hand, inflammation and endothelial 
dysfunction also play a critical role in the 
pathogenesis of hypertension.[22] systolic 
hypertension isolated with elevated pulse pressure 
is an indication of blood vessel stiffness, that can be 
considered as a marker of atherosclerosis. Several 
studies have shown a correlation between 
hypertension and CIMT thickness and blood vessel 
stiffness. [11, 13, 17] 
The important role of CIMT as a marker of 
atherosclerosis has been widely demonstrated in 
various clinical studies. In line with Shetty et al, 
which examined 100 patients with a history of 
coronary artery disease. They found that CIMT 
patients with a history of coronary artery disease 
had thicker CIMT compared to the control group (23). 
In another study, De Groot et al., found that CIMT can 
be an accurate predictor of atherosclerosis 
progression in familial hypercholesterolemia 
patients (10). Ainsworth et al., who conducted a study 
of 38 patients with carotid artery stenosis, found that 
B-mode ultrasonography of the carotid artery was 
very useful for assessing the therapeutic response in 
patients with atherosclerosis (24). 
 
Figure 5. Carotid artery CIMT Examination Using B-Mode 
Ultrasonography 
 
From meta-analysis results of 8 studies, 
Wang et al, found that eight studies involving 3329 
patients with coronary heart disease due to diabetes, 
who received antihypertensive therapy with ACE-I, 
α-blockers, or CCB compared to placebo could reduce 
CIMT thickening of 7µm/ year (p <0.01)(25). Also, 9 
other studies involving 4564 hypertensive patients 
who received ACE-I, CCB, and ARB therapy compared 
with a diuretic or β-blocker therapy, the effect of 
reducing blood pressure can cause a reduction in 
CIMT thickness of 3 µm/ year (p <0.03). Other study 
also found the superiority of CCB in reducing CIMT 
thickness of 5µm/ year in 5 studies involving 3619 
patients. This reduction of CIMT thickness was 
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not associated with differences in achieved blood 
pressure.[17] 
Our study showed that patients with the 
amlodipine treatment had the lowest CIMT thickness, 
which is 0.69 mm. Lai et al., reported the same result. 
In their study of hypertensive rats, Lai et al., 
investigated the effects of amlodipine on vascular 
smooth muscle proliferation(26). Amlodipine can 
inhibit DNA synthesis and VSMC proliferation by 
evaluating the growth factor expression impact, 
phenotype changes, and vascular smooth muscle cell 
(VSMC) proliferation in hypertensive rats. 
Amlodipine can inhibit the expression of platelet-
derived growth factor (PDGF), transforming growth 
factor β1 (TGF-β1), and basic fibroblast growth factor 
(bFGF), also mRNAs in vascular smooth muscle cells 
of hypertensive rats. Amlodipine inhibits the marker 
expression of osteopontin synthesis phenotypes and 
Gla mRNAs matrix, which shows the process of 
inhibiting VSMC growth and changing contractile 
phenotypes into synthetic phenotypes. In their study, 
Lai et al.,[26] investigated the effect of amlodipine on 
the overgrowth of VSMC culture in hypertensive rats. 
Therefore, it can be assumed that the antiproliferative 
effect of amlodipine is not associated with a decrease 
in blood pressure. 
Stevo Julius et al. [27] in the VALUE (Valsartan 
Antihypertensive Long-Term Use Evaluation) trial 
examined 15.245 patients with high-risk 
hypertension treated with valsartan or amlodipine. 
They evaluated on 7080 patients to use one kind of 
antihypertensive drug within six months. The result is 
no significant differences found between various 
cardiac endpoints, stroke, myocardial infarction, and 
death from any cause. However, they found that the 
incidence of heart failure was lower in the valsartan 
therapy group (hazard ratios: 0.63, p= 0.004, and 
0.78, p= .045, respectively). The duration of 
monotherapy in  
each group increased the relative risk of heart 
failure, and new-onset diabetes (odds ratios: 0.78, p 
= 0.012, and 0.82, p= 0.034; respectively). 
The levels of intracellular free calcium ions 
partially influenced the growth of VSMC, which 
VOCC (Voltage operated calcium channel) plays a 
vital role in the homeostasis of calcium ions in 
intracellular VSMC. CCB is bound to the voltage-
sensitive calcium channel, causing a decrease of an 
influx in extracellular calcium ion through 
sarcolemma, decreasing calcium levels in the 
cytosol, and suppressing the mechanism of 
contraction initiation from VSMC. Amlodipine is 
lipophilic, which belongs to the long-acting 
dihydropyridine CCB group, and shows slow 
association and dissociation with the calcium 
channel receptor.[28] 
In the Prospective Randomized Evaluation of 
the Vascular Effects of Norvasc Trial (PREVENT) 
study[29], which was a multicentre, randomized, 
double-blind placebo-control studies to test whether 
amlodipine can postpone the progression of early 
coronary atherosclerosis in 825 patients with 
coronary heart disease that has been proven 
angiographically or not. Based on the observation of 
36 months of therapy, there was no change 
angiography on the diameter of the segment a—
coroners who had experienced stenosis of 30%. The 
studies of B-mode ultrasonography were conducted 
to assess whether amlodipine can inhibit the process 
of atherosclerosis or not. Amlodipine is known to 
have a significant effect in slowing the progression of 
carotid artery atherosclerosis within 36 months of 
therapy. That is, the placebo group had a thick CIMT 
increasing of 0.033 mm, whereas in the amlodipine 
group had 0.0126 mm (p= 0.007). 
In the third generation of L-Type CCB, 
amlodipine has been proved to have beneficial 
effects for the treatment of heart and blood vessel 
disease. Detry et al.[30] conducted a CAPE trial, which 
resulting amlodipine could reduce the incidence of 
ischemia in patients with coronary heart disease. In 
the Coronary Angioplasty Amlodipine Restenosis 
(CAPARES Study) 
study,[31] amlodipine has been proved to reduce the 
need for revascularization in patients with stable 
angina. 
Beyond its ability to cause vasodilation through 
inhibition of calcium channels, we proved that long-
term CCB to have a beneficial effect in patients of 
coronary heart disease regardless of its impact in 
lowering blood pressure, which underline this effect. It 
was assumed to be associated with the biochemical 
characteristics of amlodipine, which the aminoethoxy 
function connected to the dihydropyridine ring, which 
would be in an electrically charged ion condition at a 
physiological-pH. This positive electrical charge which 
caused strong electrostatic interactions between 
amlodipine and phospholipids in cell membranes. 
Amlodipine's affinity to the plasma membrane would 
be maintained even in proatherogenic conditions such 
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as increased levels of cholesterol in the membrane. 
Also, with its strong affinity and supported by its 
lipophilic, amlodipine can inhibit the modified LDL 
aggregation, which is a crucial step in the process of 
foam cells mediated by oxidized and negatively 
charged lipids. The atheroprotective factor of 
amlodipine is not shared by other classes of 
antihypertensive drugs, because it does not have 
biochemical characteristics as amlodipine had. [28] 
The dihydropyridine ring structure of 
amlodipine is at the same depth as the sterol core of 
cholesterol. In this position, amlodipine can reverse 
the effects of cholesterol on membrane structure and 
function. Precisely, amlodipine can affect the ability of 
cholesterol to increase the surface area of membranes 
and bonding into a similar domain crystal, as 
illustrated in the native or oxidized cholesterol model 
in atherosclerotic cases.[32] 
Amlodipine has an antioxidant effect through 
its ability to reduce oxidative modification of LDL and 
lipid membranes. Oxidative modification of LDL and 
lipid membranes causes the formation of foam cells, 
endothelial dysfunction, and destructive 
inflammatory processes associated with 
atherosclerosis.[33] Various in vitro and in vivo studies 
showed that CCB with high lipophilic inhibits 
oxidative damage to lipids related to cell membranes 
and lipoprotein particles. [34, 35] 
Under experimentally controlled 
conditions, amlodipine can hinder the formation of 
lipid peroxidase at a concentration of 10 nmol/ L, 
without the affection of calcium channel 
modulation.[36] The antioxidant activity of 
amlodipine is an effect of the highly lipophilic of 
amlodipine and its chemical structure, which 
allows proton donor and resembles a stabilization 
mechanism that reduces free radical reactions.[37] 
By inserting into the location in the membrane 
near a conjugated double bond, the highly 
lipophilic CCB can donate protons to the lipid 
peroxidase molecule, thus inhibiting the process of 
peroxidation. Dihydropyridine (DHP) rings can 
stabilize free unpaired electrons in drug molecules. 
The reactions that describe the antioxidant effect 
of dihydropyridine CCB are defined as follows: 
(LOO● represents the lipid peroxidase molecule): 
LOO● + DHP LOO + DHP●. 
The antioxidant effect of amlodipine has 
also been observed in vivo in various experiments 
to animals, including primates, which show a 
highly significant antiatherogenic effect of this 
dihydropyridine group.[38] Including lacidipine, a 
proven substance, in preclinical study models can 
affect the thickness of the media intima and the 
amount of plaque.[11] 
From the summary of the one-way ANOVA 
of each variable that can affect CIMT, we concluded 
that there were no significant differences among 
each group in TNF-α, IL-6, LDL, Triglyceride, BMI 
and systolic blood pressure (P: 0,270; P: 0,052; P: 
0,176; P: 0,183; P: 0,057; P: 0,660). After the 
posthoc analysis, there were only two variables that 
were significantly different, which were IL-6 
between the group with ACE-I therapy, and the 
group that had not received treatment was P= 
0.017 and BMI between the group with ACE-I 
therapy and the group that had not received 
therapy was P= 0.045. 
CIMT based on Levels of TNF-α and IL-6 
In this study, the results of hypertensive 
patients who received therapy had lower levels of 
inflammatory markers compared to patients who had 
not received treatment, (TNF-α of the control group 
was 30.99 ± 6.48; ACE-I was 29.24 ± 8.35; CCB was 
16.84 ± 0.88) although after statistical tests, no 
significant difference was found (TNF-α 0.618, IL-6 P= 
0.08). 
 Inflammation demonstrated a critical role in 
the development of atherosclerosis.[39,40] Hypertension 
is a factor that influences the high level of cytokines in 
the process of atherogenesis.[41] Chae et al., in a cross-
sectional study of 508 healthy men examining the 
relationship of hypertension and atherosclerosis 
through proinflammatory effects, found that increased 
SBP, pulse pressure, and MAP were significantly 
associated with sICAM-1 and IL-6.[42] High levels of 
proinflammatory cytokines such as IL-6, supported the 
evidence for the role of proinflammatory cytokines in 
the process of atherogenesis.[43] Even before the 
myocardial infarction occurred.  
VSMC stimulation by angiotensinII (ANGII), 
which is a blood pressure regulator, caused 
inflammatory activation due to the expression and 
release of IL-6. IL-6 also caused vascular smooth 
muscle cell proliferation, which is an early sign of 
atherosclerosis due to hypertension. Hypertension can 
cause pro-inflammatory effects through increased 
oxidative stress.[44] In experimental with animal 
studies with hypertension induced by AngII,[45], it 
found an increased superoxide anion in blood vessels, 
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as well as inflammatory responses, which is aortic 
infiltration by monocytes and macrophages. 
Ang-II has a critical role in the process of 
atherosclerosis through a mechanism involved either 
dependent or independent on changes in blood 
pressure. Ang-II roles were not only increasing IL-6 
expression but also stimulates the expression of 
sICAM and infiltration of blood vessels by monocytes 
and macrophages, which can be inhibited by drugs, 
which is ACE-Inhibitor or AngiotensinII receptor 
blockers (ARBs).[39, 46] 
TNF-α is a protein that was mainly synthesized 
by monocytes and macrophages, which plays a vital 
role in the initiation of immune system activation, 
sugar, and fat metabolism. TNF-α secretion increases 
significantly in the monocytes in peripheral blood in 
patients with high blood pressure after stimulation 
with lipopolysaccharides. Activated monocytes in 
hypertensive patients can cause hypertension. TNF-α 
can trigger insulin resistance and is known to increase 
its levels in obese patients, which is a condition closely 
related to hypertension. [6, 47] 
IL-6 is a pleiotropic cytokine produced by 
various types of cells and works on various types of 
tissues and cells. In healthy organisms, IL-6 is 
excreted at low levels and maintained at this level by 
a complex regulatory network involving 
corticosteroids, catecholamines, and hormones on 
secondary sex characteristics. IL-6 gene 
expressions, especially in monocytes and 
macrophages, are quickly triggered by viruses and 
bacterial endotoxins also inflammatory cytokines 
such as IL-1 and TNF-α, PDGF (platelet-derived 
growth factor) and interferon in response to 
infections, trauma, and other stressful conditions. 
IL-6 promoter acts as a biosensor that is sensitive to 
environmental stress and contains a highly 
regulated control region that is bound to trigger 
proteins causing transcription factors related to 
pro-inflammatory or proliferation conditions, such 
as Nuclear Factor-kß (NF-kß), C/EBPß (CCAAT 
enhancer-binding protein), activator protein-1 (AP 
1) and corticosteroids.[47] IL-6 is also produced by 
adipose tissue in response to adiposity cytokines, 
which explain the relationship between obesity and 
chronic inflammation as a potential trigger of 
various cardiovascular diseases and metabolism.[48] 
During acute inflammation, IL-6 expression 
through NF-kß induces the secretion of acute-phase 
proteins from the liver. Therefore, there will be an 
increase in the expression of adhesion molecules and 
secretions from various chemoattractant factor also 
IL-6 activation may contribute to neutrophil 
recruitment into the affected tissue by endothelial 
cell activation.[49] Inactive fibroblasts (fibrocytes) 
are a part of the inflammatory milieu that produces 
MMS due to the stimulation of IL-6 to degrade the 
extracellular matrix.[50] Furthermore, IL-6 also 
regulates temporary changes in the pattern of 
leukocyte recruitment that was initially dominated 
by neutrophils to monocyte dominance, thereby 
facilitating the changes in innate immune response 
become adaptive responsiveness.[51] 
Additionally, in endothelial cells, IL-6 has been 
demonstrated to stimulate the proliferation and 
migration of circulating endothelial progenitor cells [52] 
that emphasizing the proangiogenic properties of IL-6 
ultimately. Also, IL-6 is involved in the migration of 
VSMC through mediating the effects of vascular 
endothelial growth factor (VEGF) and TNF-α.[53] 
Further, IL-6 can also stimulate VSMC proliferation with 
or without passing through PDGF (Platelet-derived 
growth factor).[54] 
The role of the Renin-angiotensin-system (RAS) 
is an important factor in blood pressure regulation since 
the kidney isolated renin. Goldblatt et al. [55] 
demonstrated the induction of hypertension by renal 
artery occlusion, and then it was found that renin as 
being responsible for this phenomenon. ANGII is a 
potent vasoconstrictor that causes aldosterone 
excretion due to sodium and water retention in the 
kidney. Thus, acute ANGII secretion prevents fatal 
hypotension. Chronic activation of ANGII can increase 
blood pressure and volume overload, thus causing 
mechanical stress on the walls of the arteries.[56] 
Activation of tissue-specific RAS also increases systemic 
RAS, which will cause an increase in vascular ROS 
production.[57] ANGII affects blood pressure through 
various mechanisms. It also has inflammatory, 
remodeling, and thrombotic effects in blood vessels due 
to the induction of pro-inflammatory cytokines IL-6 or 
TNF-α[58] also various chemokines and growth factors in 
VSMC.[59] ANGII's fibrogenic action exacerbates all of 
these factors through the induction of MMPI and PAI-
1.[60] 
Based on our investigation, although pro-
inflammatory cytokine levels were higher in the 
thickened CIMT, there were no significant differences 
(p= 0.270 for TNF-α and p= 0.052 for IL-6). Al Daghri 
et al. [61] examined pro-inflammatory cytokine levels in 
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male and female adults in Saudi Arabia, they found a 
significant relationship between hypertension and 
inflammatory markers in women, but they could not 
find in men. Then, we concluded that there was the 
effect of gender differences in the relationship between 
inflammatory markers with insulin resistance and 
hypertension, which can be caused by different fat 
distribution due to gender differences. 
Association between BMI and CIMT 
Obesity showed an association with 
increased cardiovascular risk.[62] In the U.S. Diabetes 
Prevention Program, the incidence of diabetes was 
reduced by 58%, with an average weight loss of 
5.8kg through interventions for physical activity and 
dietary patterns change.[63] It is unclear whether the 
other risk factors worsening mediated the 
relationship between obesity and cardiovascular 
risks, such as insulin resistance, components of 
metabolic syndrome, inactivity, or the pro-
inflammatory consequences of obesity.[64,65] We 
assumed that there might be many mechanisms by 
which obesity affects the cardiovascular risk that 
had not been revealed.[62] In this present study, 
patients with a higher BMI had thicker CIMT 
compared to patients with a lower BMI. However, 
after statistical analysis, there were no significant 
differences (P= 0.746). 
CIMT based on Level of LDL and Triglycerides 
The result of this present study is no 
significant differences found in CIMT between 
hypertensive patients with high LDL and 
triglyceride levels and low LDL and triglyceride 
levels (P= 0.285 and P= 1.00). The result is similar 
to Kandil et al.[66], who examined the relationship 
of inflammatory markers with CIMT in obese 
children and non-obese in Egypt, which did not 
show a significant relationship of the total 
cholesterol, triglyceride, and LDL levels with CIMT. 
Oren and Thomas’s observation[67] also found no 
significant relationship between lipids and CIMT, 
except HDL-C levels. However, Li et al.[68] reported 
a consistent relationship between LDL-C as a 
valuable predictor of CIMT in the young adult 
population. 
The oxidation of LDL is a crucial step in the 
process of atherogenesis. However, the mechanism 
of LDL oxidation is still not fully understood. 
Cholesterol uptake by LDL receptors does not allow 
cholesterol accumulation in macrophages because 
LDL receptors are downregulated by increased 
intracellular cholesterol through the mechanism of 
Sterol Regulatory Element-Binding Proteins 
(SREBPs). On the contrary, modified forms of LDL, 
such as acetylated LDL and oxidized LDL, are quickly 
captured by macrophages through Scavenger 
Receptors (SRs), causing cholesterol accumulation 
and foam cell formation because the oxidized LDL 
will upregulate scavenger receptor. [69] 
 The LDL oxidation hypothesis states the LDL 
oxidation process is the initial step in the process of 
atherosclerosis.[70] This hypothesis is supported by 
the evidence shows that oxidized LDL can trigger 
foam cells in in vitro studies. We can find oxidized 
LDL over in vivo. It has a variety of proatherogenic 
potentials such as stimulation of endothelial cells 
and monocytes that causing increased of pro-
inflammatory cytokines, chemokines and adhesion 
molecules, monocyte and macrophage stimulation 
which will increase tissue factors, matrix 
metalloproteinases, and scavenger receptors, which 
cause foam cell formation by macrophages and the 
development of atherosclerotic lesions.[70] The 
process of LDL oxidation does not occur in the 
circulation, but in the walls of blood vessels because 
serum lipoproteins are protected from oxidation by 
its retaining mechanism. For its transport, LDL 
contains a lot of alpha-tocopherol, an antioxidant 
vitamin.[71] LDL can have an exposure to various 
oxidants from cells in the subendothelial layers of the 
arterial wall. LDL oxidation can transfer via a non-
enzymatic pathway, which is by the transition of 
metal ions, hemin, and the other kind of catalysts. 
Several theories explained the oxidation of LDL 
through an enzymatic system in the arterial wall. LDL 
particles undergo oxidative modification via 
incubation in macrophage cells, endothelial cells, and 
smooth muscle cells.[72] 
Referring to this present study, we found that 
higher LDL levels in the CIMT group were <0.7, this 
could be due to false positives in the sample  
because of the lack of patient's fasting and eating 
patterns assessment so that the patient's serum 
became more turbid, which interfered the readings. 
The method of examination also determines the 
results of lipid profile testing.[73] 
CIMT and systolic blood pressure 
Hypertension is known to increase shear 
stress, which induces endothelial dysfunction, which 
is an essential step in the process of 
atherosclerosis.[74,21] endothelial dysfunctions will 
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induce various inflammatory cytokines and 
adhesion molecules, which mediate monocyte 
migration and oxidized LDL to the tunica media of 
blood vessels, which is the initial step to form foam 
cells. By the accumulation of foam cells in the tunica 
intima, numerous immunological responses will 
occur, and inflammatory cytokines will be released, 
as well as chemokines and metalloproteinases that 
will cause atherosclerosis development.[8,75] 
Lakka et al. in a 4-year cohort study of 1229 
adult men aged 42-60 years, found that SBP  and 
pulse pressure have a strong correlation with the 
process of atherosclerosis as measured by CIMT 
thickening. [44] 
According to this present study’s 
observation, the blood pressure of patients with a 
SBP of >160 had a thicker CIMT compared to 
patients with the SBP of <160 (0.70 vs. 0.77). Still, 
when conducting the statistical analysis, there was 
no significant difference between both groups (p= 
0.455). 
Bots et al.[76] in a meta-analysis stated that 
they needed some 468 patients in each group for a 
parallel clinical study to assess changes in CIMT with 
the effect of 30% for two years or 30 patients in each 
group for the effect of 100% with three years 
observation length. 
The CAMELOT study[77], examined the effect 
of antihypertensive drugs (amlodipine vs. enalapril) 
in patients with a blood pressure of <140/90 mmHg 
with a history of Coronary Artery Diseases (CAD) in 
Cardiovascular Disease (CVD) risk assessed by IVUS 
(intravenous ultrasonography) testing to compare 
the anti-atherosclerotic effects of the two drugs. The 
results of the CAMELOT study showed no   
significant difference between amlodipine and 
enalapril in CVD outcomes, but the progression of 
atherosclerosis assessed by IVUS was lower in the 
amlodipine group. 
The limitation of this study was related to the 
research method. Limited therapeutic time and the 
difficulty of determining a starting point of the study 
profoundly affected the results of the investigation. 
Besides, a minimal number of samples also affect the 
results. Thus, the research needed a longer observation 
time and a larger number of samples by looking at the 
effects of pre- and post-therapy. 
C O N C L U S I O N 
We concluded that there was a significant 
difference in CIMT between hypertensive patients who 
have not received therapy, hypertensive patients with 
ACE-I treatment and hypertensive patients with CCB 
therapy. The lowest CIMT thickness found in groups 
with CCB therapy. However, there was not enough 
evidence to say there were differences between the 
three groups on the score changes of TNF-α, IL-6, BMI, 
LDL, TG, and TDS. Thus, we assumed that the differences 
in the thickness of CIMT of the three groups were not 
dependent on TNF-α, IL-6, BMI, TG, LDL, or systolic 
blood pressure. It is in line with studies related to 
amlodipine, which has a robust lipophilic effect and 
could do protons donor, thus inhibiting oxidative stress 
due to lipid peroxidation. Moreover, because this study 
was a cross-sectional study, we could not conclude the 
cause-effect or relationship between parameters. 
We suggested other researchers conduct similar 
research with a cohort design and a larger sample size 
also longer therapy duration to obtain a valid sample 
and be able to observe the effects of pre- and post-
therapy. It is essential to consider the role of various 
other risk factors in analyzing the relationship of CIMT 
with hypertension, such as gender, age, such as obesity, 
dyslipidemia, hypertriglyceridemia, and high markers 
of inflammation. 
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